Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale.

@article{Keefe2003NeurocognitiveAI,
  title={Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale.},
  author={Richard S. E. Keefe and Richard C. Mohs and Robert M. Bilder and Philip D. Harvey and Michael F. Green and Herbert Y Meltzer and James M Gold and Mary C. Sano},
  journal={Schizophrenia bulletin},
  year={2003},
  volume={29 1},
  pages={
          45-55
        }
}
Patients with schizophrenia are severely impaired in crucial aspects of neurocognitive function. This impairment is the strongest clinical correlate of poor long-term outcome and adaptive dysfunction. Reports of neurocognitive enhancement with second generation antipsychotic medications have thus offered promise for improvement in the long-term outcome of patients with schizophrenia. However, the majority of these studies have had serious weaknesses in methodology, such as open-label design… CONTINUE READING

Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 43 CITATIONS

Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia.

  • Journal of the International Neuropsychological Society : JINS
  • 2008
VIEW 4 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

  • The New England journal of medicine
  • 2005
VIEW 6 EXCERPTS
HIGHLY INFLUENCED

Motivation and Social Cognition in Patients with Schizophrenia.

  • Journal of the International Neuropsychological Society : JINS
  • 2015
VIEW 1 EXCERPT
CITES METHODS

Neurocognitive impairment in the deficit subtype of schizophrenia

  • European Archives of Psychiatry and Clinical Neuroscience
  • 2015
VIEW 3 EXCERPTS
CITES BACKGROUND & METHODS

References

Publications referenced by this paper.
SHOWING 1-10 OF 61 REFERENCES

The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia

R.S.E. Keefe, D. O. Perkins, S. G. Silva, J. A. Lieberman
  • Schizophrenia Bulletin,
  • 1999
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Does risperidone improve verbal working memory in treatment-resistant schizophrenia?

  • The American journal of psychiatry
  • 1997
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Similar Papers

Loading similar papers…